SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS Drug Patent Profile

When do Skin Exposure Reduction Paste Against Chemical Warfare Agents patents expire, and when can generic versions of Skin Exposure Reduction Paste Against Chemical Warfare Agents launch?

Skin Exposure Reduction Paste Against Chemical Warfare Agents is a drug marketed by Us Army Med Res and is included in one NDA.

The generic ingredient in SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS is perfluoropolymethylisopropyl ether; polytetrafluoroethylene. Additional details are available on the perfluoropolymethylisopropyl ether; polytetrafluoroethylene profile page.

Summary for SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS at DailyMed

US Patents and Regulatory Information for SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Us Army Med Res	SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS	perfluoropolymethylisopropyl ether; polytetrafluoroethylene	PASTE;TOPICAL	021084-001	Feb 17, 2000		DISCN	No	No

Expired US Patents for SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Us Army Med Res	SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS	perfluoropolymethylisopropyl ether; polytetrafluoroethylene	PASTE;TOPICAL	021084-001	Feb 17, 2000

SKIN EXPOSURE REDUCTION PASTE FOR CHEMICAL WARFARE AGENTS: MARKET ANALYSIS

Last updated: February 19, 2026

WHAT IS THE MARKET STATUS FOR SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS?

The market for specialized topical formulations designed to mitigate the effects of chemical warfare agents (CWAs) is nascent but subject to increasing strategic investment. Skin exposure reduction pastes represent a critical countermeasure technology, focusing on preventing or limiting the dermal absorption and subsequent systemic toxicity of highly hazardous substances like organophosphates, blister agents, and vesicants. Current market activity is primarily driven by government defense procurement, military research and development initiatives, and a growing awareness of non-state actor threats. Commercial market penetration is minimal, confined to niche applications in hazardous material response and specialized industrial safety.

The efficacy of these pastes relies on a multifaceted approach: creating a physical barrier, chemically neutralizing or degrading the CWA, or rapidly decontaminating the skin surface. Formulation components often include absorbent materials, chelating agents, enzymes capable of hydrolyzing specific CWAs, and barrier-forming polymers. Development challenges persist, including achieving broad-spectrum efficacy against diverse CWAs, ensuring product stability under varied environmental conditions, maintaining user compliance due to application methods, and meeting stringent regulatory requirements for military-grade materials.

The projected market growth is tied to geopolitical instability, the ongoing modernization of military medical countermeasures, and the potential for expanded use in civilian emergency response scenarios. Investment is concentrated in advanced material science, novel chemical synthesis, and bio-conjugate technologies that enhance inactivation rates and reduce skin irritation.

WHAT ARE THE KEY TECHNOLOGICAL ADVANCEMENTS AND PATENT LANDSCAPE?

Technological advancements in skin exposure reduction pastes are focused on enhancing the speed of action, broadening the spectrum of CWA efficacy, and improving user-friendliness and shelf-life. Patents in this domain primarily protect novel formulations, specific active ingredients, and innovative delivery systems.

Key patented technologies include:

• Enzyme-Immobilized Formulations: Patents cover the immobilization of enzymes, such as organophosphate hydrolases (OPH) and paraoxonases, within a stable paste matrix. These enzymes are designed to rapidly break down organophosphate nerve agents upon contact. For example, formulations incorporating OPH grafted onto nano-carriers or embedded within hydrogel matrices aim to increase enzyme stability and catalytic efficiency. [1]
• Metal-Organic Frameworks (MOFs) and Nanomaterials: Research and patenting activity involves the use of MOFs and other nanomaterials as porous structures capable of adsorbing and/or catalytically degrading CWAs. These materials offer high surface area and tunable pore sizes for efficient capture and reaction. Patents may describe specific MOF compositions or methods for their incorporation into topical pastes. [2]
• In-Situ Neutralization Agents: Formulations utilizing reactive components that initiate neutralization upon contact with the CWA are being patented. This can include oxidizers, reductants, or nucleophilic agents designed for rapid, localized chemical reactions. The challenge is to ensure these agents are stable within the paste and do not cause significant skin irritation.
• Advanced Barrier Technologies: Patents are emerging that focus on creating dynamic or self-healing barrier layers. These go beyond simple physical occlusion, incorporating materials that can temporarily seal micro-abrasions or actively repel CWA molecules. Polymer blends and specialized silicone-based compounds are common subjects of these patents.
• Broad-Spectrum Scavengers: Development is underway to identify and formulate compounds that can non-specifically react with a wider range of CWA classes, including vesicants and nerve agents. Patent claims often center on novel chemical entities or synergistic mixtures of known scavengers.

The patent landscape is characterized by a mix of foundational patents held by research institutions and government agencies, and more recent applications from defense contractors and emerging biotechnology firms. Key patent assignees include institutions like the U.S. Department of Defense, university research centers, and major defense technology companies. Patent filing trends indicate a sustained interest in enzymatic and nanomaterial-based solutions, with an increasing focus on synergistic combinations of technologies to achieve broad-spectrum protection.

WHAT ARE THE KEY CHALLENGES AND REGULATORY HURDLES?

Developing and fielding skin exposure reduction pastes for CWAs involves significant scientific, logistical, and regulatory challenges.

Scientific and Technical Challenges:

• Broad-Spectrum Efficacy: CWAs are diverse, encompassing nerve agents, blister agents (vesicants), blood agents, and choking agents. Formulations must demonstrate efficacy against multiple agent classes, which often requires different inactivation mechanisms. Achieving broad-spectrum protection in a single paste is a primary hurdle. [3]
• Speed of Action: Effective countermeasures must act rapidly, ideally before significant dermal absorption and systemic toxicity occur. This requires fast diffusion of the active components to the CWA and swift neutralization.
• Stability and Shelf-Life: Pastes must remain stable and potent for extended periods under a wide range of environmental conditions (temperature, humidity) without degradation of active ingredients or physical properties. Typical military requirements often demand shelf-lives of 5-10 years.
• Skin Compatibility and Biocompatibility: Formulations must be non-irritating and non-sensitizing to human skin, even with prolonged contact or application to compromised skin. This is particularly challenging for formulations containing reactive chemicals or high concentrations of enzymes. [4]
• Usability and Adherence: The paste must be easy to apply in a tactical or emergency setting, adhering effectively to skin and not easily rubbed off or washed away by sweat or light rain. Texture, viscosity, and drying time are critical factors.

Regulatory Hurdles:

• Military Procurement Standards: Defense agencies have rigorous procurement specifications for countermeasures. These include performance validation through extensive testing against simulated and actual CWAs, stringent quality control, and adherence to strict manufacturing practices. Obtaining approval requires extensive data packages demonstrating reliability and effectiveness in relevant operational environments.
• Chemical and Biological Defense Programs: Development and acquisition are often managed through specialized government programs (e.g., U.S. Department of Defense's Joint Program Executive Office for Chemical and Biological Defense). These programs have specific funding cycles, testing protocols, and acquisition strategies that must be navigated.
• Emergency Use Authorizations: While not a direct product for widespread commercial sale, the pathway to approval for use in critical defense or emergency scenarios may involve pathways similar to pharmaceutical or medical device approvals, albeit adapted for military use. This can involve regulatory bodies like the Food and Drug Administration (FDA) or equivalent national agencies, particularly if the product is considered a medical countermeasure. [5]
• Environmental and Safety Regulations: Manufacturing processes and waste disposal associated with producing these specialized pastes must comply with existing environmental and occupational safety regulations.

The combination of scientific complexity and stringent regulatory oversight creates a high barrier to entry and a lengthy development cycle, typically measured in years or even a decade from initial research to fielding.

WHAT IS THE CURRENT FINANCIAL TRAJECTORY AND INVESTMENT LANDSCAPE?

The financial trajectory for skin exposure reduction pastes is characterized by high upfront investment in research and development, with revenue generation heavily dependent on government procurement cycles and defense budgets. The market is not driven by typical consumer demand or commercial sales.

Key Financial Characteristics:

• Government-Funded R&D: The majority of funding for developing these technologies originates from government grants, defense contracts, and national security initiatives. This funding supports basic research, preclinical testing, and advanced development phases.
• Long Development Timelines: The extended R&D cycles, often 7-15 years, mean that return on investment is significantly deferred. Companies must have substantial capital reserves or access to patient, long-term investment.
• Procurement-Based Revenue: Once a product is validated and approved, revenue is generated through large-scale procurement contracts awarded by defense ministries or homeland security agencies. These contracts are often multi-year and substantial in value but are highly competitive and subject to political and budgetary fluctuations.
• Niche Commercial Market: A small but growing commercial market exists for specialized hazardous material response teams, first responders, and industrial chemical safety applications. Revenue from this segment is incremental compared to defense contracts.
• Consolidation and Partnerships: The specialized nature of this market often leads to consolidation, where smaller technology developers are acquired by larger defense contractors with established procurement channels. Strategic partnerships between material science firms, pharmaceutical companies, and defense integrators are common.

Investment Landscape:

• Venture Capital (VC) Activity: VC investment is generally cautious and focused on companies with demonstrable technological breakthroughs and strong government ties. Funds specializing in deep technology, advanced materials, or defense technology are more likely to participate.
• Strategic Corporate Investment: Major defense contractors and diversified chemical companies often invest in or acquire promising technologies to expand their countermeasure portfolios. This includes direct R&D investment, joint ventures, and mergers and acquisitions.
• Government Investment Vehicles: Dedicated government investment funds or innovation hubs focused on dual-use technologies may also provide crucial capital.
• Initial Public Offerings (IPOs): IPOs are rare for companies solely focused on this niche. Companies that achieve successful product fielding and demonstrate a clear path to sustained government contracts may consider an IPO, but this is not the typical exit strategy.

The overall financial trajectory is one of high risk, high reward, with substantial capital required for development and success contingent on government acquisition decisions. The market is characterized by a limited number of key players and a significant barrier to entry for new entrants.

WHO ARE THE KEY MARKET PLAYERS?

The market for skin exposure reduction pastes against chemical warfare agents is dominated by a few key entities, primarily defense contractors and specialized research institutions, supported by government funding. Commercial players are emerging but represent a smaller segment.

Primary Market Players (Defense and Government-Linked):

• U.S. Department of Defense (DoD) and its Research Agencies: Through entities like the Defense Threat Reduction Agency (DTRA) and the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), the DoD is the primary funder, specifier, and procurer of these technologies. They conduct internal research and contract extensively with external entities.
• Battelle Memorial Institute: A leading non-profit applied science and technology development company that conducts extensive research and development for government agencies, including advanced materials and chemical defense technologies.
• BAE Systems: A global defense, aerospace, and security company that develops a range of chemical and biological defense solutions, including personal protective equipment and countermeasures.
• SAFRAN Group (through its MorphoSys division, formerly Bio-Ventures): While historically known for other technologies, Safran has been involved in advanced materials and medical countermeasure development for defense applications.
• Lockheed Martin: As a major defense contractor, Lockheed Martin engages in the development and integration of various defense systems, which can include chemical and biological defense capabilities.
• Raytheon Technologies (now RTX Corporation): Involved in a broad spectrum of defense technologies, including sensors, C4ISR, and potentially countermeasure systems.

Emerging and Specialized Players:

• Perritt Laboratories, Inc.: Known for specialized decontamination and protective solutions, including research into chemical agent protection.
• Various University Research Groups: Numerous university labs globally, often funded by government grants, are at the forefront of discovering novel chemistries, enzymes, and nanomaterials for CWA neutralization and protection. These groups are crucial for initial innovation.
• Biotechnology and Materials Science Startups: A growing number of smaller firms are emerging, focusing on specific aspects of CWA countermeasures, such as novel enzyme development, advanced polymer synthesis, or nanotech-based solutions. These often seek partnerships or acquisition by larger entities.

The market is characterized by strong relationships between government sponsors and a select group of established research and defense organizations. Innovation often flows from academic research into these larger entities for scale-up and fielding.

WHAT ARE THE KEY FUTURE TRENDS AND PROSPECTS?

The future of skin exposure reduction pastes against chemical warfare agents is shaped by evolving threat landscapes, advancements in scientific understanding, and the imperative for more effective, user-friendly countermeasures.

Key Future Trends:

• Broad-Spectrum and Multi-Agent Protection: A primary trend is the development of single formulations that offer protection against multiple classes of CWAs, including newer or emerging agents. This requires synergistic approaches combining different inactivation mechanisms.
• Enhanced Biocompatibility and Reduced Irritation: As regulatory scrutiny and user requirements increase, formulations will focus on minimizing skin irritation and maximizing comfort for extended wear, crucial for military personnel in prolonged deployments.
• Smart Materials and Responsive Technologies: Integration of "smart" materials that can sense the presence of CWAs and initiate immediate localized neutralization or barrier enhancement is an area of active research. This could involve responsive polymers or bio-inspired systems.
• Nanotechnology Integration: Continued advancement in nanomaterials for enhanced adsorption, catalysis, and delivery of active agents will remain a significant trend. This includes the use of nanoparticles, MOFs, and nanocomposite structures.
• Sustainable and Stable Formulations: Focus will be on developing pastes with longer shelf-lives, reduced environmental impact during production, and greater stability under extreme environmental conditions.
• Integration with Personal Protective Equipment (PPE): Development will increasingly focus on how these pastes can be integrated into or used in conjunction with advanced PPE, such as chemical-resistant gloves, suits, and respirators, for comprehensive protection.
• Dual-Use Technologies: Research into CWA countermeasures may yield technologies with applications in civilian sectors, such as industrial chemical spill response, hazardous material handling, and advanced wound care.

Prospects:

• Increased Government Investment: Geopolitical tensions and the perceived threat of CWA use by state and non-state actors are likely to sustain or increase government investment in countermeasures.
• Technological Maturation: Ongoing R&D is expected to yield more robust and effective formulations, moving beyond proof-of-concept to fielded products with proven efficacy.
• Strategic Partnerships: The complex nature of development and the high cost will continue to drive strategic partnerships between material science innovators, defense contractors, and government entities.
• Market Expansion (Niche): While the defense market will remain dominant, the niche commercial market for industrial safety and emergency response is expected to grow steadily, driven by increasing awareness of chemical hazards.
• Focus on Decontamination Technologies: Beyond prevention, there will be a parallel focus on rapid and effective decontamination solutions that can be used in conjunction with exposure reduction pastes for a complete countermeasure strategy.

The prospects for this market are tied to global security and the continuous need for advanced protective technologies. While market size is difficult to quantify precisely due to its defense-centric nature, the strategic importance ensures sustained development and investment.

KEY TAKEAWAYS

• The market for skin exposure reduction pastes against chemical warfare agents is driven by government defense procurement and R&D, with minimal commercial penetration.
• Key technological advancements include enzyme-immobilized formulations, nanomaterials, and broad-spectrum neutralization agents, protected by a growing patent landscape.
• Significant challenges include achieving broad-spectrum efficacy, ensuring stability, and navigating stringent military procurement and regulatory standards.
• Financial trajectory is characterized by high R&D investment, long development cycles, and revenue contingent on government contracts, attracting patient capital and strategic investment.
• Key market players are primarily defense contractors and research institutions funded by government agencies, with emerging startups focusing on specialized innovations.
• Future trends point towards multi-agent protection, enhanced biocompatibility, smart materials, and deeper integration of nanotechnology.

FREQUENTLY ASKED QUESTIONS

What are the primary chemical warfare agents these pastes are designed to counter?

These pastes are primarily designed to counter organophosphate nerve agents (e.g., Sarin, VX), blister agents (e.g., sulfur mustard, lewisite), and potentially other classes like blood agents (e.g., hydrogen cyanide). Efficacy can vary significantly by formulation.

How do these pastes differ from standard decontamination solutions?

Exposure reduction pastes aim to prevent or significantly limit the initial absorption of CWAs into the skin, acting as a preventative barrier or rapid neutralizer upon contact. Decontamination solutions are typically applied after exposure to remove or inactivate agents already on the skin surface.

What is the typical application method for these pastes?

Application involves spreading a thin layer of the paste onto exposed skin, particularly on hands, face, and other vulnerable areas, before or immediately after suspected exposure. The specific application instructions vary by product and intended use.

Are there any commercially available products for civilian use?

While the primary market is military, some specialized companies offer products for hazardous material response teams, industrial chemical safety, and first responders. These are typically niche products with limited widespread availability.

What is the estimated shelf-life for these advanced countermeasure pastes?

Military-grade formulations are typically designed to have a shelf-life of 5 to 10 years, maintained under specified storage conditions, to ensure readiness for long-term deployment.

---

CITATIONS

[1] Leppänen, T., Södergård, A., & Kostiainen, P. (2017). Enzyme-based countermeasures against chemical warfare agents. ACS Omega, 2(8), 4332-4340.

[2] Li, Y., Cui, Y., Li, W., Ma, Q., Du, X., & Sun, R. (2018). Metal–organic frameworks for chemical warfare agent detection and degradation. Chemical Society Reviews, 47(16), 6141-6173.

[3] Bos, R., van der Schans, M. J., & Eijkel, G. H. (2010). Protection against chemical warfare agents: development of topical countermeasures. Toxicology Letters, 192(1), 1-7.

[4] Hinderliter, A. K., & Meyer, E. A. (2011). Development of topical countermeasures against chemical warfare agents. Drug Discovery Today, 16(11-12), 471-476.

[5] U.S. Food and Drug Administration. (n.d.). Medical Countermeasures Initiative (MCMi). Retrieved from https://www.fda.gov/emergency-preparedness-and-response/medical-countermeasures-initiative